Study details							
Endnote number		Ethnicity reported?					
First author			Languag	age			
Year			Country				
			· · · · · · · · · · · · · · · · · · ·				
Eligibility checklist		Yes	No				
Population >=18				If no, exclude			
Population has mental illness				If yes, exclude			
Population is overweight/obese or at high risk				If no, exclude			
of CVD							
Treatment length >=			If no, exclude				
Active intervention is			If no, exclude				
orlistat 120mg with r							
sibutramine 10-15mg							
rimonabant 20mg on							
Control group is			If no, exclude				
lifestyle/exercise/place							
	metformin in T2DM/PCOS, or orlistat/sibutramine/rimonabant						
			If yes, evalude				
Control group is other active drug				If yes, exclude			
Randomised If no, exclude							
Is the nonviction included (places give percentages in house given)							
Is the population included (please give percentages in boxes given)							
Diabetic ( )	Diabetic Co morbidities Obese but healthy Mixed/other					ner (	
Diabetic Combinities Conscious incatury infraed/other							
Primary outcome							
Type of RCT							
	Parallel Crossov	er	Other - State				
No of arms							
	2 3		Oth	er - State			
No of relevant							
arms	2 3		Oth	er - State			
TD 4 41 41							
Treatment length							
(m) Time points (m)					1	<u> </u>	
. , ,	T/G/GE/ T/G/GE/	T / G / Gl	E / T / 4	G/GE/	T/G/GE/	T/G/GE/	
Weight:	NR NR	NR	NR	J/GE/	NR	NR	
BMI:	T/G/GE/ NR NR	T/G/GI NR	E/ T/O	G/GE/	T/G/GE/ NR	T/G/GE/ NR	
Quality							
Randomisation None Mentioned			Described **If none –				
			and (	2)	exclud	le**	
	adequate						
Allocation	None Yes						
concealment	(0) $(1)$						

Double Blinding	None Mentioned (1)	Described and (2) adequate
Flow of participants	None Described and (1) incomplete	Described and (2) adequate Total score
Is QoL measured	Yes No	
Is there a policy for continuation?	Yes No	